BEYONDSPRING INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.11 USD | +10.47% |
|
+19.89% | +134.44% |
| Apr. 22 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 15 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
| Sales 2021 | 1.35 | Sales 2022 | 1.35 | Capitalization | 73.18M |
|---|---|---|---|---|---|
| Net income 2021 | -64M | Net income 2022 | -33M | EV / Sales 2021 | 80,326,725 x |
| Net cash position 2021 | 68.79M | Net cash position 2022 | 32.31M | EV / Sales 2022 | 30,256,712 x |
| P/E ratio 2021 |
-2.75
x | P/E ratio 2022 |
-2.21
x | Employees | 73 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 73.36% |
More Fundamentals
* Assessed data
More news
Latest transcript on BeyondSpring Inc.
More recommendations
More press releases
| 1 day | +10.47% | ||
| 1 week | +19.89% | ||
| Current month | -40.90% | ||
| 1 month | -32.37% | ||
| 3 months | +143.65% | ||
| 6 months | +111.00% | ||
| Current year | +134.44% |
1 week
1.79
2.24
1 month
1.763.75
Current year
0.784.00
1 year
0.654.00
3 years
0.5433.00
5 years
0.5433.00
10 years
0.5448.49
| Managers | Title | Age | Since |
|---|---|---|---|
Lan Huang
CEO | Chief Executive Officer | 53 | 12-12-31 |
G. Kenneth Lloyd
CTO | Chief Tech/Sci/R&D Officer | 80 | 15-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Fabbio
BRD | Director/Board Member | 56 | 18-01-01 |
Lan Huang
CEO | Chief Executive Officer | 53 | 12-12-31 |
Matthew Kirkby
BRD | Director/Board Member | 55 | 16-10-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 2.11 | +10.47% | 63,530 |
| 24-04-19 | 1.91 | +6.11% | 80,217 |
| 24-04-18 | 1.8 | -2.70% | 55,502 |
| 24-04-17 | 1.85 | +2.78% | 104,609 |
| 24-04-16 | 1.8 | +2.27% | 37,542 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Calendar
2024-04-30
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +134.44% | 82.32M | |
| +2.49% | 96.73B | |
| -1.86% | 21.31B | |
| -16.61% | 21.21B | |
| -5.80% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- BYSI Stock
